Frontotemporal Lobar Degeneration clinical trials at UCSF
3 in progress, 2 open to eligible people
Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
open to eligible people ages 18-80
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.
San Francisco 5391959, California 5332921 and other locations
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
San Francisco 5391959, California 5332921 and other locations
Neurofilament Surveillance Project (NSP)
Sorry, in progress, not accepting new patients
This is a biomarker study designed to collect and analyze blood specimens from individuals carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration" (ALLFTD) study, NCT04363684. More information can be found at https://www.allftd.org/.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Frontotemporal Lobar Degeneration research studies include Howie Rosen, MD Adam Boxer, MD, PhD.
Last updated: